Degarelix and its therapeutic potential in the treatment of prostate cancer

Código QR

Degarelix and its therapeutic potential in the treatment of prostate cancer

Christian Doehn, Martin Sommerauer, Dieter JochamDepartment of Urology, University of Lübeck Medical School, Lübeck, GermanyAbstract: Degarelix is a gonadotropin-releasing hormone (GnRH) antagonist for the treatment of patients with prostate cancer in whom hormonal therapy is indic...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Christian Doehn, Martin Sommerauer, Dieter Jocham
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2009
Materias:	Prostate cancer hormonal therapy GnRH antagonist degarelix testosterone flare Geriatrics RC952-954.6
Acceso en línea:	https://doaj.org/article/1b3742e3cb0242a6b385e05f965fe3bc
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Six-month leuprorelin acetate depot formulations in advanced prostate cancer: a clinical evaluation
por: Tunn UW, et al.
Publicado: (2013)

Six-month depot formulation of leuprorelin acetate in the treatment of prostate cancer
por: Rajni Sethi, et al.
Publicado: (2009)

Comparison between selected hormone and protein levels in serum and prostate tissue homogenates in men with benign prostatic hyperplasia and metabolic disorders
por: Grzesiak K, et al.
Publicado: (2018)

Is there an optimal management for localized prostate cancer?
por: Jaspreet Singh, et al.
Publicado: (2010)

Off-label use of hormones as an antiaging strategy: a review
por: Samaras N, et al.
Publicado: (2014)

Serum total prostate-specific antigen values in men with symptomatic prostate enlargement in Nigeria: role in clinical decision-making
por: Nnabugwu II, et al.
Publicado: (2014)

Prostatectomy using different lasers for the treatment of benign prostate hyperplasia in aging males
por: Lee WC, et al.
Publicado: (2013)

Cognitive effects of testosterone and finasteride administration in older hypogonadal men
por: Borst SE, et al.
Publicado: (2014)

Geroprotectors as a therapeutic strategy for COPD – where are we now?
por: Miłkowska-Dymanowska J, et al.
Publicado: (2017)

Management of bone metastases in refractory prostate cancer – role of denosumab
por: Paller CJ, et al.
Publicado: (2012)

Metastatic castration-resistant prostate cancer in very elderly patients: challenges and solutions
por: Caffo O, et al.
Publicado: (2016)

Randomized Phase 2 Trial of Abiraterone Acetate Plus Prednisone, Degarelix, or the Combination in Men with Biochemically Recurrent Prostate Cancer After Radical Prostatectomy
por: Karen A. Autio, et al.
Publicado: (2021)

Effects of annatto-derived tocotrienol supplementation on osteoporosis induced by testosterone deficiency in rats
por: Chin KY, et al.
Publicado: (2014)

Safety and efficacy of testosterone gel in the treatment of male hypogonadism
por: Kishore M Lakshman, et al.
Publicado: (2009)

Personalized therapeutics of α1-blockers in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia
por: Zhu LL, et al.
Publicado: (2015)

Predicting Gleason score using the initial serum total prostate-specific antigen in Black men with symptomatic prostate adenocarcinoma in Nigeria
por: Nnabugwu II, et al.
Publicado: (2016)

Safety and efficacy of silodosin for the treatment of benign prostatic hyperplasia
por: Yoshida M, et al.
Publicado: (2011)

Is it necessary to cure prostate cancer when it is possible? (Understanding the role of prostate inflammation resolution to prostate cancer evolution)
por: Ronald E Wheeler
Publicado: (2007)

Análogo de GnRH disminuye la secreción de hormona folículo estimulante (FSH) en ovejas prepúberes
por: Recabarren,S E, et al.
Publicado: (2006)

Testosterone replacement therapy among elderly males: the Testim Registry in the US (TRiUS)
por: Bhattacharya RK, et al.
Publicado: (2012)

Combination therapy with dutasteride and tamsulosin for the treatment of symptomatic enlarged prostate
por: J Miller, et al.
Publicado: (2009)

Prospective investigation of change in the prostate-specific antigens after various urologic procedures
por: Park SC, et al.
Publicado: (2015)

The safety and efficacy of aspirin intake in photoselective vaporization laser treatment of benign prostate hyperplasia
por: Shao IH, et al.
Publicado: (2013)

Update on the use of dutasteride in the management of benign prostatic hypertrophy
por: Joe Miller, et al.
Publicado: (2007)

Docetaxel treatment in the elderly patient with hormone refractory prostate cancer
por: Victoria J Sinibaldi
Publicado: (2008)

Modulating testosterone pathway: a new strategy to tackle male skin aging?
por: Bernard P, et al.
Publicado: (2012)

Efficacy and safety of prostate artery embolization on lower urinary tract symptoms related to benign prostatic hyperplasia: a systematic review and meta-analysis
por: Wang XY, et al.
Publicado: (2016)

The safety and efficacy of aspirin intake in photoselective vaporization laser treatment of benign prostate hyperplasia
por: Shao IH, et al.
Publicado: (2013)

Efficacy and safety of tamsulosin hydrochloride 0.2 mg and combination of tamsulosin hydrochloride 0.2 mg plus solifenacin succinate 5 mg after transurethral resection of the prostate: a prospective, randomized controlled trial
por: Shin YS, et al.
Publicado: (2016)

Critical appraisal of cabazitaxel in the management of advanced prostate cancer
por: Sumanta Kumar Pal, et al.
Publicado: (2010)

The therapeutic effects of the physician-older patient relationship: Effective communication with vulnerable older patients
por: Summer L Williams, et al.
Publicado: (2007)

Targeting of intracellular Ca2+ stores as a therapeutic strategy against age-related neurotoxicities
por: Joshua Goldberg, et al.
Publicado: (2020)

Protocolo largo con análogos de GnRH versus protocolo corto con antagonistas: ¿existen diferencias en cuanto a los resultados de los ciclos de FIV-ICSI?
por: Blasco G,Laura, et al.
Publicado: (2011)

Risk Factors of Emergency Room Visits for Bleeding Complications Following Transurethral Procedures in the Treatment of Benign Prostatic Hyperplasia: A Retrospective Cohort Study
por: Teng TC, et al.
Publicado: (2021)

Hormonal determinants of the severity of andropausal and depressive symptoms in middle-aged and elderly men with prediabetes
por: Rabijewski M, et al.
Publicado: (2015)

Conservative Management of Uterine Adenomyosis: Medical vs. Surgical Approach
por: Christina Anna Stratopoulou, et al.
Publicado: (2021)

Bisphosphonates in the management of postmenopausal osteoporosis – optimizing efficacy in clinical practice
por: Oliver Bock, et al.
Publicado: (2008)

Growth hormone and aging: A challenging controversy
por: Andrzej Bartke
Publicado: (2008)

Osteoporosis in men: its pathophysiology and the role of teriparatide in its treatment
por: Claudia Gagnon, et al.
Publicado: (2008)

An open-label, prospective interventional study of the tolerability and efficacy of 0.4 mg oral tamsulosin oral controlled absorption system in men with lower urinary tract symptoms associated with benign prostatic hyperplasia who are unsatisfied with treatment with 0.2 mg tamsulosin
por: Yang PS, et al.
Publicado: (2018)